White Light Stimulation at Gamma Frequency to Modify the Aβ42 and tau Proteins in SH-SY5Y Cells

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

American Journal of Alzheimers Disease and Other Dementias Pub Date : 2024-03-04 DOI:10.1177/15333175241236251

Yang-Pei Chang, Ching-Fang Chien, Ling-Chun Huang, Chih-Pin Chuu, Hsi-Wen Chang, Tzyh-Chyuan Hour, Yuan-Han Yang

{"title":"White Light Stimulation at Gamma Frequency to Modify the Aβ42 and tau Proteins in SH-SY5Y Cells","authors":"Yang-Pei Chang, Ching-Fang Chien, Ling-Chun Huang, Chih-Pin Chuu, Hsi-Wen Chang, Tzyh-Chyuan Hour, Yuan-Han Yang","doi":"10.1177/15333175241236251","DOIUrl":null,"url":null,"abstract":"BackgroundNon-invasive 40 Hz gamma frequency stimulation has shown improved cognition and memory recall in Alzheimer’s disease (AD).PurposeThe present study investigates the effects of white light stimulation at gamma frequency on SH-SY5Y cells using Delta M + BrainCare Light without causing discomfort.MethodsSH-SY5Y cells were exposed to The Delta M + BrainCare Light for 15, 30, 45, and 60 minutes. The secretion of amyloid-β42 (Aβ42), p-AKT (Ser473), AKT, p-mTOR (Ser2448), mTOR, p-4E-BP1 (Thr37/46), 4E-BP1, p-tau (Thr181), and tau were analyzed. Aβ42 fibril aggregation and phagocytosis of FITC-Aβ42 in BV-2 cells were also observed.ResultsDelta M + BrainCare Light reduced tau, AKT, and p-mTOR and increased p-4E-BP1 in SH-SY5Y cells. Further, it inhibited secretion and aggregation of Aβ42, alongside increased phagocytosis in microglial cells.ConclusionThese findings underscore the potential of the Delta M + BrainCare Light in mitigating the associated proteins and pathways implicated in AD.","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":"144 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15333175241236251","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

BackgroundNon-invasive 40 Hz gamma frequency stimulation has shown improved cognition and memory recall in Alzheimer’s disease (AD).PurposeThe present study investigates the effects of white light stimulation at gamma frequency on SH-SY5Y cells using Delta M + BrainCare Light without causing discomfort.MethodsSH-SY5Y cells were exposed to The Delta M + BrainCare Light for 15, 30, 45, and 60 minutes. The secretion of amyloid-β42 (Aβ42), p-AKT (Ser473), AKT, p-mTOR (Ser2448), mTOR, p-4E-BP1 (Thr37/46), 4E-BP1, p-tau (Thr181), and tau were analyzed. Aβ42 fibril aggregation and phagocytosis of FITC-Aβ42 in BV-2 cells were also observed.ResultsDelta M + BrainCare Light reduced tau, AKT, and p-mTOR and increased p-4E-BP1 in SH-SY5Y cells. Further, it inhibited secretion and aggregation of Aβ42, alongside increased phagocytosis in microglial cells.ConclusionThese findings underscore the potential of the Delta M + BrainCare Light in mitigating the associated proteins and pathways implicated in AD.

查看原文本刊更多论文

伽马频率的白光刺激改变 SH-SY5Y 细胞中的 Aβ42 和 tau 蛋白质

背景无创40赫兹伽马频率刺激已显示可改善阿尔茨海默病（AD）患者的认知和记忆回忆。目的本研究使用Delta M + BrainCare Light白光刺激伽马频率对SH-SY5Y细胞的影响，且不会引起不适。分析淀粉样蛋白-β42（Aβ42）、p-AKT（Ser473）、AKT、p-mTOR（Ser2448）、mTOR、p-4E-BP1（Thr37/46）、4E-BP1、p-tau（Thr181）和 tau 的分泌。结果Delta M + BrainCare Light降低了SH-SY5Y细胞中的tau、AKT和p-mTOR，增加了p-4E-BP1。此外，它还抑制了 Aβ42 的分泌和聚集，同时增加了小胶质细胞的吞噬作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).